33
Participants
Start Date
June 30, 2011
Primary Completion Date
July 31, 2014
Study Completion Date
December 31, 2018
Amrubicin
35 mg/m2; IV on days 1-3 each 3 week cycle
Indiana University, Indianapolis
Stanford University School of Medicine, Stanford
Collaborators (1)
Celgene
INDUSTRY
Heather Wakelee
OTHER